A Phase III Open-Label, Outpatient Extension Study to Assess the Long-Term Safety and Efficacy of Two Dose Levels of a Modified Release Formulation of Study Drug in Adult Primary Insomnia Patients with Sleep Maintenance Difficulties

Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy, Safety and Tolerability of Two Doses of a Once-Daily Oral Formulation of Study Drug in Subjects with Major Depressive Disorder for a Treatment Period of Eight Weeks

Analysis of Survey Data and Validation of the Original Dementia Progression Scale

An Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of Study Drug in the Treatment of Mild Cognitive Impairment

Study Drug Versus Study Drug in the Treatment of Major Depressive Disorder

A Multi-Center, Double-Blind, Placebo-Controlled, Randomized Parallel Group Evaluation of the Efficacy of a Flexible Dose of Study Drug versus Placebo as Add-On Therapy in Schizoprhenia

A Randomized, Open Label, Long Term, Multi Center Study of the Safety of Study Drug (for Alcohol and/or Opiate Dependence)

An Open-Label Study of Tolerability, Clinical Response, and Satisfaction in Adult Bipolar I Subjects Optimizing Initiation of Therapy Using Administration of Study Precautions and Study Drug Titration Packs

A Randomized Double-Blind Study of Study Drug Versus Study Drug in the Treatment of Schizophrenia

A Dose-Ranging Placebo-Controlled Study of Study Drug at the doses of 0.5 mg, 2 mg, and 8 mg for 12 Weeks in Patients with Mild-to-Moderate Alzheimer’s Disease